Clinical Trials

Drug Development Drug Efficacy Phase 3 Trials Randomized Controlled Trials Patient Care Research Studies Phase 2 Trials Randomized Trials Drug Safety Experimental Drugs

Pilot Trial Signals Low-Dose Lithium May Slow Verbal Memory Decline in Mild Cognitive Impairment

The findings prompt plans for a biomarker-guided trial focusing on amyloid-positive patients.

Aristotle Flags Guardant Health as Key Q4 Contributor on Strong Results, Acquisition News

Insmed Sets $1 Billion 2026 Brinsupri Target After Strong First Full Quarter

Compass Pathways’ Psilocybin Therapy Hits Phase 3 Goal in Treatment-Resistant Depression

Genentech Licenses SanegeneBio RNAi Program in Deal Worth Up to $1.7 Billion

Regeneron Beats Q4 and Charts 2026 Catalysts With FDA Decisions and Phase III Push

Randomized Trial Finds Solriamfetol Improves Alertness in Early-Morning Shift Workers

Merck Lifts Mid-2030s Revenue Goal to $70 Billion From Emerging Businesses

Cochrane Update Finds No Clear Benefit of Cannabis-Based Medicines for Neuropathic Pain

Novo’s Wegovy Pill Posts Quick Uptake, Boosting Shares as Oral GLP‑1 Battle Nears

UK Trial Finds FDA-Cleared ADHD Nerve Stimulation Ineffective in Children and Teens

Rakuten Medical, Lotte Biologics Sign Manufacturing Deal for Photoimmunotherapy Supply

Oxford Review Finds GLP-1 Weight Loss Largely Lost Within About Two Years After Stopping

Aktis Oncology Soars 24% in Nasdaq Debut After $318 Million IPO

Finger-Prick Dried Blood Test Flags Alzheimer’s Biomarkers in European Study

Shenzhuo Formula Improves Kidney Function Versus Irbesartan in 24-Week Diabetes Trial

FDA Clears Wegovy Pill, Handing Novo Nordisk a Short-Term Edge in Obesity-Drug Race

FDA Grants National Priority Voucher to J&J’s Tecvayli–Darzalex Combo in Multiple Myeloma

Terns’ TERN-701 Shows Strong CML Responses in CARDINAL, Setting 320 mg and 500 mg Phase 2 Doses

Paris Court Delays Trial of Joyeux and Fourtillan in Illegal Clinical Tests Case